ClinicalTrials.gg
RecruitingNCT04339699STITCHUpdated Mar 23, 2026

NobleStitch EL STITCH Trial is a PFO Comparative Trial

An interventional study of NobleStitch™EL Suture Mediated Closure System and Amplatzer PFO Occluder in Foramen Ovale, Patent and Stroke, Ischemic, sponsored by Nobles Medical Technologies II Inc. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Nobles Medical Technologies II Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
640
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies in Foramen Ovale, Patent with a site in United States — 10 open to participants now, 12 under way, 1 of them phase 3. Foramen Ovale, Patent · United States.

Planned enrollment
5th of 25
640 · median 168
Started
2021
with 2 others
No phase
15 of 36
5 open now
Primary completion
2026-12
later than 4 of 11 live
Registered
25th of 36
by date

Among the 36 studies in Foramen Ovale, Patent with a site in United States, this one is the 5th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2021, is one of 15 with no phase, reaches primary completion later than 4 of the 11 other live ones, and was the 25th registered.

Foramen Ovale, Patent

137 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.

Browse Foramen Ovale, Patent studies →

Open to participants now

10 of the 36 studies in Foramen Ovale, Patent with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Foramen Ovale, Patent studies recruiting now, 11 (32%) set no upper age limit and 19 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Foramen Ovale, Patent with a site in United States, or all of them as a file.
02

Study summary

STITCH - Prospective Multi-Center Comparative Parallel Concurrent Study of the NobleStitch™ EL versus FDA-approved Amplatzer Occluder device for closure of Patent Foramen Ovale to prevent recurrent Ischemic stroke.

Read the detailed description

To demonstrate the non-inferiority of the NobleStitch™ EL with medical management in both safety and effectiveness compared to the FDA-approved Amplatzer Occluder with medical management for PFO Closure.

To demonstrate that the NobleStitch EL does not increase the incidence of ischemic stroke compared to published medical management data.

03

Conditions studied

  • Foramen Ovale, Patent
  • Stroke, Ischemic

Keywords

  • Patent Foramen Ovale
  • Stroke
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female ages 18 - 60 years old
  • A PFO and a Cryptogenic Stroke verified by a neurologist
  • Stroke is defined as an acute focal neurological deficit, presumed to be due to focal ischemia, and either:

    • Symptoms persisting ≥24 hours, or
    • Symptoms persisting \<24 hours with Magnetic Resonance or CT findings of a new, neuroanatomical relevant infarct
  • Cryptogenic stroke was defined as a stroke of unknown cause
  • Prolonged cardiac rhythm monitoring (recommended 30 days and not less than 24 hours required)
  • Intra and extracranial artery imaging: Magnetic Resonance Angiography, CT angiography, or contrast angiography, or contrast angiography or echocardiography of the carotid arteries to rule out ischemic stroke associated with atherosclerotic plaque, arterial dissection, or other vascular diseases. (The aortic arch may also be evaluated by TEE).
  • Hypercoagulable state assessment to rule out an underlying hypercoagulable state

Exclusion criteria

Exclusion Criteria:

  • Female participant who is pregnant, lactating or planning a pregnancy during the course of the study
  • Age \<18 or > 60 years of age
  • Previous myocardial infarction or unstable angina within 6 months
  • mitral or aortic valve stenosis or severe regurgitation
  • \<50 percent
  • Progressive neurological dysfunction or reduced
  • Contrast allergy
  • Atrial Septal Defect (baseline left to right shunt assessed by TEE or other congenital heart diseases
  • Active Endocarditis
  • Perspective participants with known causes of Ischemic Stroke
  • Arterial dissection
  • or unsuitable for antiplatelet agents or oral anticoagulants
  • Perspective participants with prosthetic heart valves
  • Uncontrolled diabetes Mellitus
  • Pulmonary hypertension
  • Uncontrolled systemic hypertension
  • Intracranial pathology
  • Neurological deficits not due to stroke that may affect neurologic assessments
  • Active disease
  • Active infection
  • Alcohol and/or drug abuse
  • A requirement for chronic anticoagulation therapy that cannot be discontinued
  • Anatomic features (inability to achieve vascular access)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
640 participants (estimated)

Study arms

  • Active comparator
    NobleStitch™EL

    Participants treated with the NobleStitch™EL device

    Device: NobleStitch™EL Suture Mediated Closure System

  • Active comparator
    Amplatzer PFO Occluder

    Participants treated with the Amplatzer PFO Occluder device

    Device: Amplatzer PFO Occluder

Interventions

  • DeviceNobleStitch™EL Suture Mediated Closure System

    Percutaneous closure of Patent Foramen Ovale (PFO) using NobleStitch™EL suture Medicate Closure System

  • DeviceAmplatzer PFO Occluder

    Percutaneous closure of Patent Foramen Ovale (PFO) using Amplatzer PFO Occluder

06

What researchers measure

Primary outcomes

  1. Effective PFO closure rate of the NobleStitch EL

    Effectiveness PFO closure rate of NobleStitch EL suture mediated closure with medical management compared to Amplatzer PFO occluder with medical management for PFO closure. Effective PFO closure rate defined as Grade 0 or 1 shunt at rest and during Valsalva at 6 month post closure attempts

    Time frame: 6 months

Secondary outcomes

  1. Decreased event rate of recurrent ischemic stroke following PFO closure using NobleStitch EL

    Safety of NobleStitch EL suture mediated closure system as compared to Amplatzer PFO Occluder Procedural and device related adverse event rate at 6 month follow up recurrent ischemic stroke through 5 years follow up

    Time frame: 5 years

Other outcomes

  1. The occurrence of recurrent ischemic stroke post procedural of patent foramen ovale closure

    Examination of Recurrent Ischemic Stroke through 5 year follow up. Comparison of the rate of Stroke associated with the NobleStitch EL procedure to that expected with medical management

    Time frame: 5 Years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Gaspardone A, De Marco F, Sgueglia GA, De Santis A, Iamele M, D'Ascoli E, Tusa M, Corciu A, Mullen M, Nobles A, Carminati M, Bedogni F. Novel percutaneous suture-mediated patent foramen ovale closure technique: early results of the NobleStitch EL Italian Registry. EuroIntervention. 2018 Jun 8;14(3):e272-e279. doi: 10.4244/EIJ-D-18-00023. PubMed 29616629 ↗

Individual participant data

Plan to share: Yes — Individual participant data (IPD) from the completed STITCH clinical trial that underlie the results reported in the Study, shall after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol

Time frame: Immediately the following publication and ending 24 months after publication

Access criteria: Will be available to Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. It will be available for Individual participant data meta-analysis

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.

Of 31 interventional studies with no phase under Foramen Ovale, Patent, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 100. This study's planned 71 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2020
First posted
Apr 9, 2020
StartActual
Jan 1, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04339699
Lead sponsor
Nobles Medical Technologies II Inc
Responsible party
Sponsor
First posted
Apr 9, 2020
Start date
Jan 1, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Mar 23, 2026

Study contacts

James A Thompson, MD
Contact
jthomp80@jhmi.edu
727-767-7328
Anthony Nobles, Phd
Contact
anobles@noblesmed2.com
714-427-0398
Anthony A Nobles, PhD
study director · Nobles Medical Technologies II Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion